Angiotensin 1/2 (5-7): Vasoconstrictor Peptide for Blood Pressure and RAS Research

Executive Summary: Angiotensin 1/2 (5-7) is a defined oligopeptide (H2N-Ile-His-Pro-OH) with a molecular weight of 365.43 Da, acting as a potent vasoconstrictor in blood pressure regulation (APExBIO). The peptide is a terminal fragment of angiotensin II and is produced by enzymatic cleavage within the renin-angiotensin system (RAS) (Oliveira et al., 2025). Angiotensin 1/2 (5-7) enhances receptor-mediated interactions such as spike–AXL binding relevant to COVID-19 pathogenesis (DOI). Its high purity (98.36% by HPLC) and validated solubility in water, ethanol, and DMSO enable reproducible workflows. The product, distributed by APExBIO, supports rigorous hypertension and infectious disease studies through precise control of RAS modulation.

Biological Rationale

Angiotensin 1/2 (5-7) is a biologically active peptide derived from angiotensinogen, a liver-produced globulin. The peptide consists of three amino acids: isoleucine, histidine, and proline. It forms through sequential cleavage of angiotensin I and angiotensin II, key intermediates in the RAS (Oliveira et al., 2025). The RAS system is crucial for regulating blood pressure, fluid balance, and electrolyte homeostasis. Angiotensin 1/2 (5-7) acts primarily as a vasoconstrictor, contributing to increases in systemic arterial pressure. The peptide's dipsogenic effects—stimulating thirst—further support homeostatic responses under hypovolemia or hypotension. As a terminal C-fragment of angiotensin II, Angiotensin 1/2 (5-7) represents a mechanistically distinct probe for dissecting RAS signaling in both physiological and pathophysiological contexts (Related Article). This article extends prior summaries by detailing the peptide’s role in viral receptor binding and translational applications.

Mechanism of Action of Angiotensin 1/2 (5-7)

Angiotensin 1/2 (5-7) exerts biological effects by mimicking the terminal tripeptide of angiotensin II, directly inducing vasoconstriction in vascular smooth muscle (Oliveira et al., 2025). While full-length angiotensin II primarily activates the AT1 receptor, terminal fragments such as (5-7) can modulate receptor interactions, including non-canonical targets. Recent evidence demonstrates that Angiotensin 1/2 (5-7) enhances the binding of the SARS-CoV-2 spike protein to the AXL receptor, which is significant in cells with low ACE2 expression. This effect is both sequence- and length-dependent, with shorter angiotensin peptides showing greater potentiation of spike–AXL binding than their parent molecules. The sequence H2N-Ile-His-Pro-OH is sufficient to trigger these effects, suggesting direct or allosteric modulation of receptor affinity. Additionally, the peptide’s dipsogenic activity is mediated via central nervous system pathways, likely involving hypothalamic osmoreceptors. Thus, Angiotensin 1/2 (5-7) serves as a versatile molecular tool to dissect both vascular and viral entry signaling pathways.

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) is formed by C-terminal truncation of angiotensin II and retains vasoconstrictor activity (Oliveira et al., 2025).
• Peptides such as Angiotensin 1/2 (5-7) potentiate SARS-CoV-2 spike–AXL binding more than full-length angiotensin II (2.7-fold increase with angiotensin IV; similar effect for (5-7)) (DOI).
• Angiotensin 1/2 (5-7) is highly soluble: ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, and ≥50 mg/mL in water (at room temperature) (APExBIO).
• APExBIO supplies Angiotensin 1/2 (5-7) at >98.3% purity (HPLC) with mass spectrometric confirmation (Product Page).
• Infectious disease research protocols use the peptide to study RAS–viral receptor crosstalk, as discussed in recent workflow reviews (Related Article).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is validated for:

• Modeling vasoconstriction and blood pressure regulation in vitro and in vivo.
• Studying RAS peptide–receptor interactions, especially non-canonical targets (e.g., AXL).
• Enhancing the mechanistic understanding of spike protein binding in SARS-CoV-2 research.
• Serving as a control or probe in cell viability, proliferation, and cytotoxicity assays (Lab Solutions Article—this article updates protocol parameters and troubleshooting for A1049 use).

Limits and Misconceptions:

Common Pitfalls or Misconceptions

• Not a full agonist at AT1/AT2: Angiotensin 1/2 (5-7) does not fully replicate the signaling profile of angiotensin II (1-8); its receptor selectivity and potency differ (DOI).
• Not interchangeable with angiotensin II in animal models: Dose–response and pharmacodynamic properties are distinct and must be titrated separately.
• Not a diagnostic reagent: The peptide is for research use only (RUO); not for clinical diagnostics or therapy.
• Stability limits: Long-term storage of solutions is not recommended; use freshly prepared aliquots to maintain integrity (APExBIO).
• No direct antiviral effect: While it modulates spike protein–receptor binding, it does not neutralize SARS-CoV-2 infectivity.

Workflow Integration & Parameters

For experimental reproducibility, Angiotensin 1/2 (5-7) (SKU A1049) is supplied as a solid and should be stored at -20°C. Reconstitute with water, ethanol, or DMSO at validated concentrations (≥36.5 mg/mL in DMSO; ≥50 mg/mL in ethanol or water). Avoid repeated freeze–thaw cycles. Use freshly prepared solutions for critical experiments. Quality control includes HPLC (98.36% purity) and mass spectrometric verification. Shipping is on blue ice for small molecule stability. For workflow-specific troubleshooting and advanced use cases, see this protocol review (this article extends inter-assay guidance with new viral binding data), and compare with this thought-leadership piece (which our article updates with recent purity and COVID-19 interaction findings).

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a rigorously characterized research peptide enabling targeted modulation of renin-angiotensin system pathways. Its role as a vasoconstrictor and as a modulator of viral receptor interactions (notably, spike–AXL) is now well established. Researchers can rely on APExBIO’s high-purity A1049 kit for reproducible hypertension, cardiovascular, and infectious disease models. Future work will refine its application in translational and systems medicine, expanding benchmarks for both RAS signaling and viral pathogenesis studies. For complete specifications and ordering, see the Angiotensin 1/2 (5-7) product page.